程序性死亡因子1/程序性死亡因子配体1在乳腺癌免疫治疗中的意义

doi:10.3877/cma.j.issn.1674-0807.2020.06.011

程序性死亡因子1(PD-1)和程序性死亡因子配体1(PD-L1)作为免疫检查点中的共抑制信号，参与了肿瘤细胞免疫逃逸过程。近年来，免疫治疗逐渐成为了肿瘤靶向治疗的新思路。笔者概述了PD-1/PD-L1的表达机制及其在不同类型乳腺癌免疫治疗中的研究进展，介绍了免疫相关不良反应的发生情况，以供同行参考。

关键词: 乳腺肿瘤, 免疫治疗, PD-1, PD-L1

表1 PD-1/PD-L1抑制剂用于乳腺癌治疗的临床研究概况

研究名称	NCT编号	受试者	治疗方案	结果	试验分期
TONIC^[56]	NCT02499367	67例TNBC	分为5组：多柔比星组、环磷酰胺组、顺铂组、放射治疗组(8 Gy×3)及无诱导治疗组。2周后，均接受3 mg/kg nivolumab治疗	总体ORR 20%，顺铂组23%和多柔比星组35%。多柔比星组和顺铂组检测到PD-1/PD-L1和细胞毒性T细胞途径的免疫相关基因上调	Ⅱ
KEYNOTE-012^[31]	NCT01848834	111例TNBC	每2周静脉注射pembrolizumab，10 mg/kg	ORR 18.5%，mPFS 1.9个月，mOS 10.2个月	Ⅰb
KETNOTE-086队列A^[57]	NCT02447003	170例mTNBC	每3周静脉注射pembrolizumab 200 mg，持续2年	总体ORR 5.3%，DCR 7.6%；PD-L1阳性患者ORR 5.7%，DCR 9.5%；mPFS2个月，mOS 8.9个月	Ⅱ
KETNOTE-086队列B^[58]	NCT02447003	84例PD-L1阳性mTNBC	每3周静脉注射pembrolizumab 200 mg，持续2年	ORR 21.4%，DCR 23.8%，mPFS 2.1个月，mOS 18.0个月	Ⅱ
KEYNOTE-355^[59]	NCT02819518	847例mTNBC	pembrolizumab+化疗组与安慰剂+化疗组	中位随访时间：17.5个月比15.5个月；CPS≥10患者的PFS：9.7个月比5.6个月；CPS≥1患者的PFS：7.6个月比5.6个月	Ⅲ
I-SPY 2^[60]	NCT01042379	104例TNBC和113例HR(+)/HER-2(-)乳腺癌	标准新辅助化疗(紫杉醇、多柔比星、环磷酰胺)加pembrolizumab治疗，对照组不接受pembrolizumab治疗	TNBC患者中：pembrolizumab组与对照组的pCR：60.0%比20.0%；HR(+)/HER-2(-)患者中，34%比13%	Ⅱ
MDPL3280^[61]	NCT01375842	27例TNBC	分别以15、20 mg/kg及1 200 mg固定剂量，静脉注射atezolizumab，每3周1次	ORR 24%，2例完全缓解，3例部分缓解，24周后PFS为33%	Ⅰa
Impassion130^[52]	NCT02425891	902例mTNBC	白蛋白结合型紫杉醇+atezolizumab组与白蛋白结合型紫杉醇+安慰剂组	PFS: 7.5个月比5.0个月；mOS: 21.0个月比18.7个月；PD-L1阳性患者中mOS：25.0个月比18.0个月	Ⅲ
JAVELIN^[62]	NCT01772004	174例MBC	每2周静脉注射avelumab，10 mg/kg，治疗2～50周	ORR 3.0%, TNBC组ORR 5.2%；所有病例中PD-L1阳性与阴性患者的ORR为16.7%比1.6%，TNBC组中ORR比为22.2%比2.6%	Ⅰ
GeparNuevo^[63]	NCT02685059	174例原发性TNBC	durvalumab/安慰剂+白蛋白结合型紫杉醇联用剂量密集型EC(表柔比星+环磷酰胺)方案	durvalumab组与安慰剂组的pCR 53.4%比44.2%，PD-L1阳性肿瘤存在pCR率升高趋势	Ⅱ
MEDI4736^[64]	NCT02489448	TNBC	3、10 mg/kg durvalumab+白蛋白结合型紫杉醇治疗	10 mg/kg durvalumab的给药方式是安全的，该实验第二阶段正在进行，预计招募50例患者入组	Ⅰ
ICONIC^[65]	NCT02904226	晚期实体瘤	A组：JTX-2011的3+3剂量递增设计；B组：JTX-2011的3+3剂量递增设计联用nivolumab；C组：在超过3种高表达ICOS的肿瘤中，应用JTX-2011；D组：在超过5种高表达ICOS的肿瘤中，JTX-2011与nivolumab联用	将评价ORR、反应持续时间、DCR、PFS、OS，目前未完成	Ⅰ/Ⅱ
联合放射治疗^[66]	NCT02639026	MBC	durvalumab+tremelimumab联合放射治疗，放射剂量8 Gy×3组比17 Gy×1组	受试者招募中	Ⅰ

表1 PD-1/PD-L1抑制剂用于乳腺癌治疗的临床研究概况

研究名称	NCT编号	受试者	治疗方案	结果	试验分期
TONIC^[56]	NCT02499367	67例TNBC	分为5组：多柔比星组、环磷酰胺组、顺铂组、放射治疗组(8 Gy×3)及无诱导治疗组。2周后，均接受3 mg/kg nivolumab治疗	总体ORR 20%，顺铂组23%和多柔比星组35%。多柔比星组和顺铂组检测到PD-1/PD-L1和细胞毒性T细胞途径的免疫相关基因上调	Ⅱ
KEYNOTE-012^[31]	NCT01848834	111例TNBC	每2周静脉注射pembrolizumab，10 mg/kg	ORR 18.5%，mPFS 1.9个月，mOS 10.2个月	Ⅰb
KETNOTE-086队列A^[57]	NCT02447003	170例mTNBC	每3周静脉注射pembrolizumab 200 mg，持续2年	总体ORR 5.3%，DCR 7.6%；PD-L1阳性患者ORR 5.7%，DCR 9.5%；mPFS2个月，mOS 8.9个月	Ⅱ
KETNOTE-086队列B^[58]	NCT02447003	84例PD-L1阳性mTNBC	每3周静脉注射pembrolizumab 200 mg，持续2年	ORR 21.4%，DCR 23.8%，mPFS 2.1个月，mOS 18.0个月	Ⅱ
KEYNOTE-355^[59]	NCT02819518	847例mTNBC	pembrolizumab+化疗组与安慰剂+化疗组	中位随访时间：17.5个月比15.5个月；CPS≥10患者的PFS：9.7个月比5.6个月；CPS≥1患者的PFS：7.6个月比5.6个月	Ⅲ
I-SPY 2^[60]	NCT01042379	104例TNBC和113例HR(+)/HER-2(-)乳腺癌	标准新辅助化疗(紫杉醇、多柔比星、环磷酰胺)加pembrolizumab治疗，对照组不接受pembrolizumab治疗	TNBC患者中：pembrolizumab组与对照组的pCR：60.0%比20.0%；HR(+)/HER-2(-)患者中，34%比13%	Ⅱ
MDPL3280^[61]	NCT01375842	27例TNBC	分别以15、20 mg/kg及1 200 mg固定剂量，静脉注射atezolizumab，每3周1次	ORR 24%，2例完全缓解，3例部分缓解，24周后PFS为33%	Ⅰa
Impassion130^[52]	NCT02425891	902例mTNBC	白蛋白结合型紫杉醇+atezolizumab组与白蛋白结合型紫杉醇+安慰剂组	PFS: 7.5个月比5.0个月；mOS: 21.0个月比18.7个月；PD-L1阳性患者中mOS：25.0个月比18.0个月	Ⅲ
JAVELIN^[62]	NCT01772004	174例MBC	每2周静脉注射avelumab，10 mg/kg，治疗2～50周	ORR 3.0%, TNBC组ORR 5.2%；所有病例中PD-L1阳性与阴性患者的ORR为16.7%比1.6%，TNBC组中ORR比为22.2%比2.6%	Ⅰ
GeparNuevo^[63]	NCT02685059	174例原发性TNBC	durvalumab/安慰剂+白蛋白结合型紫杉醇联用剂量密集型EC(表柔比星+环磷酰胺)方案	durvalumab组与安慰剂组的pCR 53.4%比44.2%，PD-L1阳性肿瘤存在pCR率升高趋势	Ⅱ
MEDI4736^[64]	NCT02489448	TNBC	3、10 mg/kg durvalumab+白蛋白结合型紫杉醇治疗	10 mg/kg durvalumab的给药方式是安全的，该实验第二阶段正在进行，预计招募50例患者入组	Ⅰ
ICONIC^[65]	NCT02904226	晚期实体瘤	A组：JTX-2011的3+3剂量递增设计；B组：JTX-2011的3+3剂量递增设计联用nivolumab；C组：在超过3种高表达ICOS的肿瘤中，应用JTX-2011；D组：在超过5种高表达ICOS的肿瘤中，JTX-2011与nivolumab联用	将评价ORR、反应持续时间、DCR、PFS、OS，目前未完成	Ⅰ/Ⅱ
联合放射治疗^[66]	NCT02639026	MBC	durvalumab+tremelimumab联合放射治疗，放射剂量8 Gy×3组比17 Gy×1组	受试者招募中	Ⅰ

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]．CA Cancer J Clin, 2020，70(1): 7-30.
[2]	Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: areview[J]. JAMA Oncol, 2019.doi: 10.1001/jamaoncol.2018.7147.
[3]	赵丹，王伏生，路晓庆，等. 乳腺癌免疫治疗中程序性细胞死亡受体1及其配体通路作用的相关研究进展[J]．中国医药，2018，13(7): 1106-1109.
[4]	张凤春，张硕渊，陈天恩，等. PD-1/PD-L1通路在三阴性乳腺癌预后预测及治疗中的意义[J]．上海交通大学学报(医学版), 2020，40(1): 128-133.
[5]	曾榃伦，李佳玄，尹钟平，等. PD-1/PD-L1抑制剂在三阴性乳腺癌免疫治疗中的研究进展[J]．中国免疫学，2019，35(19): 2423-2429.
[6]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011，144(5): 646-674.
[7]	王勒，郑红梅，吴新红，等. 免疫微环境在三阴性乳腺癌中的研究进展[J]．医学综述，2019，25(20): 4029-4033.
[8]	Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992，11(11): 3887-3895.
[9]	Seliger B. Basis of PD1/PD-L1 therapies[J]. J Clin Med, 2019，8(12): 2168.
[10]	Marinelli O, Annibali D, Aguzzi C, et al. The controversial role of PD-1 and its ligands in gynecological malignancies[J]. Front Oncol, 2019，9: 1073.
[11]	Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas[J]. Hum Pathol, 2016，47(1): 52-63.
[12]	Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers[J]. Nature, 2016，534(7607): 402-406.
[13]	Platanias LC. Mechanisms of type-Ⅰ- and type-Ⅱ-interferon-mediated signalling[J]. Nat Rev Immunol, 2005，5(5): 375-386.
[14]	Zhang X, Zeng Y, Qu Q, et al. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer[J]. Int J Clin Oncol, 2017，22(6): 1026-1033.
[15]	Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-，TRAF6-，and MEK-dependent pathway[J]. Blood, 2007，110(1): 296-304.
[16]	Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J]. J Thorac Oncol, 2015，10(6): 910-923.
[17]	Castagnoli L, Cancila V, Cordoba-Romero SL, et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer[J]. Oncogene, 2019，38(21): 4047-4060.
[18]	Yang F, Sun L, Li Q, et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities[J]. EMBO J, 2012，31(1): 110-123.
[19]	Rohit B, David J. Immunohistology of the breast[M]//David J. Diagnostic immunohistochemistry: theranostic and genomic applications. Philadelphia: Elsevier，2010：718-771.
[20]	孔令慧，王金花，郭志娟，等. cyclin D1与PD-L1在不同分子亚型浸润性乳腺癌中的表达及相关性分析[J]．癌症进展，2019，17(19): 2306-2308，2313.
[21]	Lim SO, Li CW, Xia W, et al. EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape[J]. Cancer Res, 2016，76(5): 1284-1296.
[22]	Feng J, Yang H, Zhang Y, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells[J]. Oncogene, 2017，36(42): 5829-5839.
[23]	夏想厚，尹文娟，扈杰杰，等. 赖氨酸单甲基转移酶SETD8上调三阴性乳腺癌细胞程序性死亡因子配体1蛋白表达及其临床意义[J]．中华实验外科杂志，2019，36(6): 1030-1032.
[24]	Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1[J]. Cancer Cell, 2018，33(2): 187-201.
[25]	Li CW, Lim SO, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity[J]. Nat Commun, 2016，7: 12 632.
[26]	李燕. 乳腺癌新辅助化疗前后PD-L1的表达与肿瘤浸润免疫细胞及化疗疗效的相关性研究[D]．泸州：西南医科大学，2017.
[27]	Yuan C, Liu Z, Yu Q, et al. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters[J]. Sci Rep, 2019，9(1): 14 356.
[28]	李蕾，陈平，潘燕，等. PD-L1与肿瘤浸润性淋巴细胞在浸润性导管乳腺癌中表达的相关性[J]．广东医学，2019，40(5): 702-705.
[29]	Akiki M, Haddad FG, Kourie HR, et al. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer[J]. Biomark Med, 2019，13(18): 1539-1541.
[30]	Reisenbichler ES, Han G, Bellizzi A, et al. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer[J]. Mod Pathol, 2020，33(9): 1746-1752.
[31]	Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study[J]. J Clin Oncol, 2016，34(21): 2460-2467.
[32]	Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type[J]. Cancer Epidemiol Biomarkers Prev, 2014，23(12): 2965-2970.
[33]	范晓杰，王心然，岳萌，等. PD-L1在三阴性乳腺癌组织中表达及其与脉管生成的关系[J]．中国肿瘤生物治疗杂志，2019，26(11): 1229-1234.
[34]	Dill EA, Gru AA, Atkins KA, et al. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors[J]. Am J Surg Pathol, 2017，41(3): 334-342.
[35]	Kassardjian A, Shintaku PI, Moatamed NA. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas[J]. PLoS One, 2018，13(4): e0195958.
[36]	Thompson ED, Taube JM, Asch-Kendrick RJ, et al. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast[J]. Mod Pathol, 2017，30(11): 1551-1560.
[37]	徐程，潘贝晶，平国强，等. 伴腋窝淋巴结转移的乳腺浸润性导管癌PD-L1的表达及临床病理特征[J]．中华病理学杂志，2018，47(1): 59-60.
[38]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012，366(26): 2443-2454.
[39]	Lv S, Wang S, Qiao G, et al. Functional CD3(+)CD8(+)PD1(-) T cell accumulation and PD-L1 expression increases during tumor invasion in DCIS of the breast[J]. Clin Breast Cancer, 2019，19(5): e617-e623.
[40]	Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition[J]. Cancer Discov, 2017，7(10): 1098-1115.
[41]	Polamraju P, Haque W, Cao K, et al. Comparison of outcomes between metaplastic and triple-negative breast cancer patients[J]. Breast, 2020，49: 8-16.
[42]	Joneja U, Vranic S, Swensen J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1[J]. J Clin Pathol, 2017，70(3): 255-259.
[43]	Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy[J]. NPJ Breast Cancer, 2017，3: 8.
[44]	Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J]. Clin Cancer Res, 2014，20(19): 5064-5074.
[45]	Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase Ⅲ randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199[J]. J Clin Oncol, 2014，32(27): 2959-2966.
[46]	Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication[J]. Breast Cancer, 2017，24(1): 3-15.
[47]	钟亚春，陆璇，杨泳，等. PD-1、PDL-1和T淋巴细胞亚群在乳腺癌中的表达及价值[J]．重庆医学，2019，48(18): 3134-3137，3142.
[48]	卢子龙，耿庆. 免疫检查点抑制剂在非小细胞肺癌治疗中的研究进展[J]．疑难病杂志，2020，19(3): 311-316.
[49]	Mills AM, Gottlieb C, Ring KL. PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions[J]. Gynecol Oncol Rep, 2017，20: 135-136.
[50]	Saleh R, Taha RZ, Sasidharan Nair V, et al. PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer[J]. Cancers (Basel), 2019，11(8): 1050.
[51]	Mohan N, Hosain S, Zhao J, et al. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1(+) triple negative breast cancer cells[J]. Oncoimmunology, 2019，8(9): e1624128.
[52]	Narayan P, Wahby S, Gao JJ, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1[J]. Clin Cancer Res, 2020，26(10): 2284-2289.
[53]	Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2020，6(3): 375-384.
[54]	刘洋，曹雪涛. 肿瘤免疫治疗和化疗的协同效应及其作用机制[J]．中国肿瘤生物治疗杂志，2014，21(1): 98-103.
[55]	Chia S, Bedard PL, Hilton J, et al. A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND.229)[J]. Oncologist, 2019，24(11): 1439-1445.
[56]	Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med，2019，25(6): 920-928.
[57]	Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019，30(3): 397-404.
[58]	Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019，30(3): 405-411.
[59]	Castan JC, Guo Z, Karantza V, et al. KEYNOTE-355: Randomized, double-blind, phase Ⅲ study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)[J]．J Clin Oncol，2018，36(suppl 5): abstr TPS18.
[60]	Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2[J]. J Clin Oncol，2017，35(suppl 15): 506.
[61]	Emens L, Braiteh F, Cassier P, et al. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)[J]. Cancer Res, 2015，75: PD1-6.
[62]	Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study[J]. Breast Cancer Res Treat, 2018，167(3): 671-686.
[63]	Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019，30(8): 1279-1288.
[64]	Pusztai L, Silber A, Hofstatter EW, et al. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage Ⅰ-Ⅲ triple negative breast cancer (TNBC): A Phase Ⅰ/Ⅱ trial[J]．J Clin Oncol，2017，35(suppl 15): 572.
[65]	Sears O, Burris H, Tolcher A, et al. Abstract CT035: ICONIC: Phase 1/2 trial of ICOS agonist JTX-2011 alone and in combination with nivolumab (nivo)[J]. Cancer Res, 2017，77(13 suppl): CT035.
[66]	Abramson Cancer Center of the University of Pennsylvania.Trial of hypofractionated radiotherapy in combination with MEDI4736 and tremelimumab for patients with metastatic melanoma and lung, breast and pancreatic cancers[EB/OL]. [2020-04-20]. URL
[67]	Teufel A, Zhan T, Härtel N, et al. Management of immune related adverse events induced by immune checkpoint inhibition[J]. Cancer Lett, 2019，456: 80-87.
[68]	胡琪，于雪峰，黎雨，等. 抗PD-1/PD-L1免疫检查点抑制剂的皮肤免疫相关不良反应的研究进展[J]．现代肿瘤医学，2020，28(4): 652-655.
[69]	Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: asystematic review and meta-analysis[J]. JAMA Oncol, 2018，4(12): 1721-1728.
[70]	Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis[J]. BMJ, 2018，363: k4226.

[1]	河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[2]	刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[3]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[4]	邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[5]	程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[6]	涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[7]	朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[8]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9]	韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[10]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[11]	张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[12]	王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[13]	赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[14]	陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[15]	王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Significance of programmed death-1 and programmed death-ligand 1 in immunotherapy of breast cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Significance of programmed death-1 and programmed death-ligand 1 in immunotherapy of breast cancer